A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Active:	No
Cancer Type:	Lung Cancer Solid Tumor Unknown Primary	NCT ID:	NCT03600883
Trial Phases:	Phase I Phase II	Protocol IDs:	20170543 (primary) NCI-2018-01725
Eligibility:	18 - 100 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Amgen, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03600883

Summary

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C
mutant advanced solid tumors.

Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in
adult subjects with KRAS p.G12C mutant advanced solid tumors.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.